Cytosorbents Management
Management criteria checks 2/4
Cytosorbents' CEO is Phil Chan, appointed in Jan 2009, has a tenure of 15.42 years. total yearly compensation is $1.33M, comprised of 36.2% salary and 63.8% bonuses, including company stock and options. directly owns 1.36% of the company’s shares, worth $591.50K. The average tenure of the management team and the board of directors is 4.1 years and 9.8 years respectively.
Key information
Phil Chan
Chief executive officer
US$1.3m
Total compensation
| CEO salary percentage | 36.2% |
| CEO tenure | 15.4yrs |
| CEO ownership | 1.4% |
| Management average tenure | 4.1yrs |
| Board average tenure | 9.8yrs |
Recent management updates
Recent updates
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Mar 16
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Jan 06Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
Nov 10Shareholders Should Be Pleased With Cytosorbents Corporation's (NASDAQ:CTSO) Price
Jul 13Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
May 16We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Mar 08CytoSorbents secures $4.3M contract by U.S. Department of Defense
Oct 06CytoSorbents stock rises on US DoD contract to develop device for universal plasma
Sep 09We're A Little Worried About Cytosorbents' (NASDAQ:CTSO) Cash Burn Rate
Sep 02CytoSorbents gets reimbursement for CytoSorb in Turkey
Aug 23CytoSorbents stock rises 10% as Israel approves coverage for CytoSorb system
Aug 17Cytosorbents GAAP EPS of -$0.25 misses by $0.13, revenue of $8.5M misses by $1.06M
Aug 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$28m |
| Dec 31 2023 | US$1m | US$483k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$23m |
| Jun 30 2023 | n/a | n/a | -US$26m |
| Mar 31 2023 | n/a | n/a | -US$31m |
| Dec 31 2022 | US$1m | US$483k | -US$33m |
| Sep 30 2022 | n/a | n/a | -US$41m |
| Jun 30 2022 | n/a | n/a | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$29m |
| Dec 31 2021 | US$2m | US$483k | -US$25m |
| Sep 30 2021 | n/a | n/a | -US$16m |
| Jun 30 2021 | n/a | n/a | -US$10m |
| Mar 31 2021 | n/a | n/a | -US$9m |
| Dec 31 2020 | US$1m | US$456k | -US$8m |
| Sep 30 2020 | n/a | n/a | -US$11m |
| Jun 30 2020 | n/a | n/a | -US$17m |
| Mar 31 2020 | n/a | n/a | -US$18m |
| Dec 31 2019 | US$1m | US$438k | -US$19m |
| Sep 30 2019 | n/a | n/a | -US$21m |
| Jun 30 2019 | n/a | n/a | -US$17m |
| Mar 31 2019 | n/a | n/a | -US$19m |
| Dec 31 2018 | US$1m | US$400k | -US$17m |
| Sep 30 2018 | n/a | n/a | -US$15m |
| Jun 30 2018 | n/a | n/a | -US$14m |
| Mar 31 2018 | n/a | n/a | -US$10m |
| Dec 31 2017 | US$828k | US$378k | -US$9m |
Compensation vs Market: Phil's total compensation ($USD1.33M) is above average for companies of similar size in the US market ($USD680.27K).
Compensation vs Earnings: Phil's compensation has increased whilst the company is unprofitable.
CEO
Phil Chan (54 yo)
15.4yrs
Tenure
US$1,333,402
Compensation
Dr. Phillip P. Chan, M.D., Ph D., is known as Phil has been the Chief Executive Officer at Cytosorbents Corporation since January 2009 and served as its President until May 2020. Dr. Chan serves as a Partn...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.4yrs | US$1.33m | 1.36% $ 591.5k | |
| President & COO | 18.9yrs | US$1.11m | 0.52% $ 224.9k | |
| Chief Financial Officer | less than a year | US$816.08k | 0.54% $ 236.0k | |
| Chief Medical Officer | 4.1yrs | US$1.06m | 0.17% $ 75.2k | |
| Vice President of Investor Relations & Corporate Communications | 3yrs | no data | no data | |
| Executive Vice President of Sales & Marketing | 12yrs | no data | no data | |
| Senior Vice President of Business Development | 1.4yrs | no data | no data | |
| Senior Vice President of Global Regulatory Affairs | 1.4yrs | no data | no data | |
| Executive | no data | no data | no data | |
| Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 7yrs | US$97.32k | no data |
4.1yrs
Average Tenure
67.5yo
Average Age
Experienced Management: CTSO's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 15.9yrs | US$1.33m | 1.36% $ 591.5k | |
| Co-Chairman of Cardiac Surgery Advisory Board & Consultant | 9.8yrs | US$97.32k | no data | |
| Member of Critical Care Advisory Board | no data | no data | no data | |
| Independent Director | 9.6yrs | US$118.47k | 0.064% $ 27.6k | |
| Independent Director | 17.2yrs | US$101.93k | 0.036% $ 15.6k | |
| Member of Critical Care Advisory Board | no data | no data | no data | |
| Chairman of the Trauma Advisory Board | 11.2yrs | no data | no data | |
| Member of Trauma Advisory Board | no data | no data | no data | |
| Member of Trauma Advisory Board | 11.2yrs | no data | no data | |
| Chairman of Cardiac Surgery Advisory Board | 9.8yrs | no data | no data | |
| Member of Cardiac Surgery Advisory Board | 9.8yrs | no data | no data | |
| Independent Chairman of the Board | 8.9yrs | US$161.70k | 0.10% $ 44.9k |
9.8yrs
Average Tenure
63yo
Average Age
Experienced Board: CTSO's board of directors are considered experienced (9.8 years average tenure).